Cargando…

Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice

The influenza virus is a serious threat to public health worldwide. A novel avian influenza A (H7N9) virus with a mortality rate of approximately 30% has been identified as an unusually dangerous virus for humans by the World Health Organization. Pathogenic H7N9 continue to represent a public health...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Huilin, Yao, Wei, Yu, Dongshan, Weng, Tianhao, Wang, Frederick X.C., Wu, Xiaoxin, Wu, Haibo, Cheng, Linfang, Lu, Xiangyun, Wu, Nanping, Chen, Honglin, Li, Lanjuan, Yao, Hangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696145/
https://www.ncbi.nlm.nih.gov/pubmed/29190879
http://dx.doi.org/10.18632/oncotarget.20064
_version_ 1783280384326238208
author Ou, Huilin
Yao, Wei
Yu, Dongshan
Weng, Tianhao
Wang, Frederick X.C.
Wu, Xiaoxin
Wu, Haibo
Cheng, Linfang
Lu, Xiangyun
Wu, Nanping
Chen, Honglin
Li, Lanjuan
Yao, Hangping
author_facet Ou, Huilin
Yao, Wei
Yu, Dongshan
Weng, Tianhao
Wang, Frederick X.C.
Wu, Xiaoxin
Wu, Haibo
Cheng, Linfang
Lu, Xiangyun
Wu, Nanping
Chen, Honglin
Li, Lanjuan
Yao, Hangping
author_sort Ou, Huilin
collection PubMed
description The influenza virus is a serious threat to public health worldwide. A novel avian influenza A (H7N9) virus with a mortality rate of approximately 30% has been identified as an unusually dangerous virus for humans by the World Health Organization. Pathogenic H7N9 continue to represent a public health concern, and several candidate vaccines are currently in development. We generated candidate H7N9 vaccine strains using reverse genetics, consisting of hemagglutinin and neuraminidase genes derived from a human H7N9 virus and the remaining genes from the PR8 (A/PuertoRico/8/34 (H1N1)) virus. This H7N9 vaccine exhibited superior efficacy when combined with MF59 compared to other adjuvants. Immunized BALB/c mice were followed to determine the duration of the protective immune response. Antibody levels decreased to between one-half and one-eighth of the peak values four months after the final dose of the vaccine. Previously vaccinated mice received an A/Zhejiang/DTID-ZJU01/2013 H7N9 challenge six months post-vaccination, and all remained protected. We also verified that MF59 enhanced the HI, MN, and IgG antibody titers to influenza antigens. The humoral immune response and Th2 cytokine production following influenza challenge was potently induced in the animals that received the split vaccine. Therefore, the split H7N9 influenza vaccine with the MF59 adjuvant could effectively induce antibody production and protect mice from H7N9 virus challenge even after six months.
format Online
Article
Text
id pubmed-5696145
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56961452017-11-29 Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice Ou, Huilin Yao, Wei Yu, Dongshan Weng, Tianhao Wang, Frederick X.C. Wu, Xiaoxin Wu, Haibo Cheng, Linfang Lu, Xiangyun Wu, Nanping Chen, Honglin Li, Lanjuan Yao, Hangping Oncotarget Research Paper The influenza virus is a serious threat to public health worldwide. A novel avian influenza A (H7N9) virus with a mortality rate of approximately 30% has been identified as an unusually dangerous virus for humans by the World Health Organization. Pathogenic H7N9 continue to represent a public health concern, and several candidate vaccines are currently in development. We generated candidate H7N9 vaccine strains using reverse genetics, consisting of hemagglutinin and neuraminidase genes derived from a human H7N9 virus and the remaining genes from the PR8 (A/PuertoRico/8/34 (H1N1)) virus. This H7N9 vaccine exhibited superior efficacy when combined with MF59 compared to other adjuvants. Immunized BALB/c mice were followed to determine the duration of the protective immune response. Antibody levels decreased to between one-half and one-eighth of the peak values four months after the final dose of the vaccine. Previously vaccinated mice received an A/Zhejiang/DTID-ZJU01/2013 H7N9 challenge six months post-vaccination, and all remained protected. We also verified that MF59 enhanced the HI, MN, and IgG antibody titers to influenza antigens. The humoral immune response and Th2 cytokine production following influenza challenge was potently induced in the animals that received the split vaccine. Therefore, the split H7N9 influenza vaccine with the MF59 adjuvant could effectively induce antibody production and protect mice from H7N9 virus challenge even after six months. Impact Journals LLC 2017-08-08 /pmc/articles/PMC5696145/ /pubmed/29190879 http://dx.doi.org/10.18632/oncotarget.20064 Text en Copyright: © 2017 Ou et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Ou, Huilin
Yao, Wei
Yu, Dongshan
Weng, Tianhao
Wang, Frederick X.C.
Wu, Xiaoxin
Wu, Haibo
Cheng, Linfang
Lu, Xiangyun
Wu, Nanping
Chen, Honglin
Li, Lanjuan
Yao, Hangping
Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
title Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
title_full Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
title_fullStr Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
title_full_unstemmed Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
title_short Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice
title_sort longevity of protective immune responses induced by a split influenza a (h7n9) vaccine mixed with mf59 adjuvant in balb/c mice
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696145/
https://www.ncbi.nlm.nih.gov/pubmed/29190879
http://dx.doi.org/10.18632/oncotarget.20064
work_keys_str_mv AT ouhuilin longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT yaowei longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT yudongshan longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT wengtianhao longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT wangfrederickxc longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT wuxiaoxin longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT wuhaibo longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT chenglinfang longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT luxiangyun longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT wunanping longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT chenhonglin longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT lilanjuan longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice
AT yaohangping longevityofprotectiveimmuneresponsesinducedbyasplitinfluenzaah7n9vaccinemixedwithmf59adjuvantinbalbcmice